Xencor Inc (XNCR) company profile
Close on Nov 18, 2026Market cap $2.56BP/E –Yield –
About Xencor
Pharmaceutical Preparations, SIC 2834
The company is a clinical-stage biopharmaceutical firm focused on discovering and developing engineered antibody therapeutics for patients with cancer and autoimmune diseases. It leverages proprietary protein engineering technologies to design modular Fc domains and multi-specific antibody formats under the XmAb platform, which feature improved half-life, cytotoxic activity, and targeted immune mechanisms. Its pipeline includes wholly owned clinical-stage candidates such as XmAb819 and XmAb541 for oncology indications, and XmAb942, plamotamab, and XmAb657 for autoimmune and inflammatory conditions. The company targets patients with serious unmet medical needs and serves commercial biopharmaceutical partners through collaborative research, product licensing, and platform technology access agreements.
The organization conducts clinical trial programs across Phase 1 and Phase 2 stages and advances partnered candidates through licensing alliances with global reach. Partnered programs utilizing its proprietary technology have produced three commercialized medicines marketed internationally, along with multiple candidates in Phase 2 and Phase 3 development worldwide. The provided text does not disclose the company's founding year, website address, or headquarters location.
Summary of the business section of Xencor's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Xencor Inc
- Headquarters
- Pasadena, CA
- Address
- 465 N. Halstead St., Suite 200 91107
- Phone
- (626) 305-5900
- Website
- xencor.com
- Employees
- 260, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- KPMG LLP, San Diego, California
Stock & identifiers
- Ticker
- XNCR
- Exchange
- Nasdaq
- IPO date
- Dec 3, 2013
- Shares outstanding
- 74M, Jul 31, 2026
- Public float
- $555.94M, Jun 30, 2025
- Filer category
- Accelerated filer
- SEC CIK
- 1326732
- CUSIP
- 98401F105
- ISIN
- US98401F1057
- FIGI
- BBG0026ZG4W0
- Share class FIGI
- BBG0026ZG4X9
- LEI
- 549300V5IF65437JKG30
- EIN
- 20-1622502
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Bassil I. Dahiyat | PRESIDENT & CEO, Director | 546,316 |
| Bart Jan Cornelissen | SR. VICE PRESIDENT & CFO | 65,798 |
| John R. Desjarlais | SR. VICE PRESIDENT & CSO | 263,831 |
| Celia Eckert | SVP, GENERAL COUNSEL | 76,918 |
| Nancy Valente | EVP, Chief Development Officer | 49,169 |
| Richard J. Ranieri | Director | 18,514 |
| Todd E. Simpson | Director | 23,988 |
| Ellen Feigal | Director | 22,642 |
| Alan Bruce Montgomery | Director | 25,849 |
| Kurt A. Gustafson | Director | 25,011 |
| Raymond Joseph Deshaies | Director | 10,302 |
| Barbara Klencke | Director | 29,974 |
| Kevin Charles Gorman | Director | 21,680 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $5.52M | $1.49M | $1.39M | $35 | $120 |
| FY2024 | $6.81M | $2.56M | $3.14M | $53 | $91 |
| FY2023 | $7.97M | $6.15M | $3.12M | $49 | $92 |
| FY2022 | $7.71M | -$770.56K | $2.44M | $60 | $89 |
| FY2021 | $5.37M | $317.34K | $2.13M | $92 | $99 |
| FY2020 | $4.48M | $6.73M | $1.26M | $127 | $126 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Stock awards | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|
| Bassil I. Dahiyat, Ph.D. President, Chief Executive Officer and Director | $742.80K | $1.55M | $2.73M | $490.25K | $8.25K | $5.52M | -19% |
| Bart Jan Cornelissen Chief Financial Officer | $491.60K | $310.58K | $515.71K | $243.34K | $81.16K | $1.64M | -56% |
| John R. Desjarlais, Ph.D. Chief Scientific Officer | $547.90K | $422.39K | $701.37K | $301.35K | $9.25K | $1.98M | -30% |
| Celia E. Eckert General Counsel | $491.60K | $310.58K | $515.71K | $243.34K | $9.25K | $1.57M | -20% |
| Nancy K. Valente, M.D. Former Chief Development Officer | $249.42K | – | – | – | $181.35K | $430.77K | -85% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Dec 3, 2013
- Securities offered
- 12,730,000
- Exchange
- Nasdaq
- First trading day
- Dec 3, 2013
- First-day close
- $8.34
- Lock-up ends (est.)
- Jun 1, 2014
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 260 full-time employees, of which 212 were engaged in research and development activities, and 48 were engaged in business development, information systems, facilities, human resources, or administrative support.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Mar 13, 2025 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Mar 5, 2025 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Jun 26, 2015 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Dec 3, 2013 | IPO | Initial public offering priced (424B4 prospectus) |
| Nov 7, 2013 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?